Trials / Completed
CompletedNCT04270760
Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction - DOSE Finding Study
A Double-blind, Randomized, Placebo-controlled Phase 2 Study to Evaluate Efficacy, Safety, and Tolerability of Olpasiran (AMG 890) in Subjects With Elevated Lipoprotein(a)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 281 (actual)
- Sponsor
- Amgen · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
Evaluate the effect of olpasiran administered subcutaneously (SC) compared with placebo, on percent change from baseline in lipoprotein(a) (Lp\[a\]).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Olpasiran | Dose 1 Dose 2 Dose 3 Dose 4 |
| DRUG | Placebo | Dose 5 |
Timeline
- Start date
- 2020-07-28
- Primary completion
- 2021-12-27
- Completion
- 2022-11-08
- First posted
- 2020-02-17
- Last updated
- 2026-03-31
- Results posted
- 2023-08-23
Locations
36 sites across 7 countries: United States, Australia, Canada, Denmark, Iceland, Japan, Netherlands
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04270760. Inclusion in this directory is not an endorsement.